关于万泽实业股份有限公司 法律意见书 2025 年股权激励计划预留授予事项的 法律意见书 中国 深圳 福田区益田路6001号太平金融大厦11、12层 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road No.6001, Futian District, Shenzhen 518038 电话(Tel)：(0755)88265288 传真（Fax)：（0755）88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www.sundiallawfirm.cn | 释 义 | | | --- | --- | | 第一节 法律意见书引言 | 3 | | 第二节 法律意见书正文 . | | | 本次激励计划的批准和授权 . | 1 - 1 - 5 | | 本次调整 . | | | ן ו 本次激励计划的授予日 . | 1 - 1 - 8 | | 四、 本次激励计划的授予条件 | 8 | | 五、 结论性意见 . | 10 | 广东信达律师事务所 关于万泽实业股份有限公司 2025 年股权激励计划预留授 ...

万泽实业股份有限公司 WEDGE INDUSTRIAL CO.,LTD. 章 程 二〇二五年十月 | 1 | | | --- | --- | | P | ﺎﻡ . | | 1 | | | | 1 | | 第二章 | 经营宗旨和范围 | 5 | | --- | --- | --- | | 第三章 | 股 份 | 6 | | 第四章 | 股东和股东会 | 9 | | 第五章 | 董事会 | 27 | | 第六章 | 总经理及其他高级管理人员 | 42 | | 第七章 | 财务会计制度、利润分配和审计 | 44 | | 第二节 | 内部审计 | 49 | | 第八章 | 通知和公告 | 51 | | --- | --- | --- | | 第九章 | 合并、分立、增资、减资、解散和清算 | 52 | | 第十章 | 特别条款 | 56 | | 第十一章 | 修改章程 | 57 | | 第十二章 | 附则 | 57 | 第一章 总则 第一条 为维护万泽实业股份有限公司（以下简称"公司"）、股东、职工和债 权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证 ...

证券代码：000534 证券简称：万泽股份 公告编号: 2025-092 万泽实业股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 现场会议召开时间：2025年10月29日下午14时30分； 网络投票时间： 通过深圳证券交易所交易系统投票时间为：2025年10月29日9:15-9:25， 9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年10月29 日9:15-15:00。 2、会议召开地点 深圳市福田区福强路2016号云顶翠峰裙楼一楼会议室。 3、会议召开方式 本次股东大会采用现场表决与网络投票相结合的方式召开。 4、会议召集人 公司董事会。 1 5、会议主持人 经半数以上董事推举，本次会议由公司董事蔡勇峰先生主持。 6、会议的出席情况 参加现场会议和网络投票的股东（或股东代理人）合计144人，代表有 表 ...

广东信达律师事务所 股东大会法律意见书 中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road 6001, Futian District, Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www. sundiallawfirm.com 广东信达律师事务所 关于万泽实业股份有限公司 2025 年第四次临时股东大会的法律意见书 信达会字[2025]第 331 号 致：万泽实业股份有限公司 广东信达律师事务所（下称"信达"）接受万泽实业股份有限公司（下称"贵 公司"或"公司"）的委托，指派信达律师出席贵公司 2025 年第四次临时股东大 会（下称"本次股东大会"），对贵公司本次股东大会的合法性进行见证，并出具 本《广东信达律师事务所关于万泽实业股份有限公司 2025 年第四次临时股东大 会的法律意见书》（下称"《 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4][6]. Core Views - The company achieved a revenue of 941 million yuan in the first three quarters of 2025, representing a year-over-year growth of 21.00%. The net profit attributable to shareholders reached 170 million yuan, up 22.45% year-over-year [1]. - The company's high-temperature alloy division is focused on high-temperature alloy products for aviation engines and is actively expanding its market presence [1]. - The report highlights a significant increase in sales volume of lower-margin high-temperature alloys, which has impacted the overall gross margin [1][2]. Financial Performance - In Q3 2025, the company reported a revenue of 315 million yuan, a year-over-year increase of 14.79%, and a net profit of 51 million yuan, up 23.90% year-over-year [1]. - The gross margin for the first three quarters of 2025 decreased by 3.27 percentage points to 73.61%, while the net margin fell by 1.33 percentage points to 15.98% [1]. - The company has improved its expense management, with a reduction in the overall expense ratio by 3.77 percentage points to 53.13% [2]. Research and Development - The company has increased its R&D expenditure by 21.85% year-over-year, amounting to 136 million yuan, which reflects its commitment to innovation [2]. - The fifth phase of the company's stock incentive plan was announced, aiming to enhance the motivation and creativity of its core team [3]. Future Projections - The company is expected to achieve net profits of 245 million yuan, 353 million yuan, and 447 million yuan for the years 2025, 2026, and 2027, respectively [4][5]. - The current stock price corresponds to a price-to-earnings ratio of 34x for 2025, 24x for 2026, and 19x for 2027 [4][5].

智通财经APP讯，万泽股份(000534.SZ)披露2025年第三季度报告，公司前三季度实现营收9.41亿元，同 比增长21%;归母净利润1.7亿元，同比增长22.45%;扣非净利润1.57亿元，同比增长31.79%;基本每股收益 0.3402元。 ...

每经AI快讯，万泽股份（SZ 000534，收盘价：16.26元）10月26日晚间发布三季度业绩公告称，2025年 前三季度营收约9.41亿元，同比增加21%；归属于上市公司股东的净利润约1.7亿元，同比增加22.45%； 基本每股收益0.3402元，同比增加21.24%。 截至发稿，万泽股份市值为83亿元。 每经头条（nbdtoutiao）——金价大"崩盘"：12年来最大单日跌幅背后，四大指标早已预警！后市怎么 走？华尔街吵翻了 （记者 曾健辉） ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥315,174,307.88, representing a 14.79% increase year-over-year[5] - Net profit attributable to shareholders was ¥50,530,383.99, up 23.90% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥46,373,908.04, an increase of 38.15% year-over-year[5] - The company's basic earnings per share for the period was ¥0.1005, a 20.94% increase compared to the same period last year[5] - The company reported total operating revenue of ¥940,601,669.56 for the current period, an increase of 20.92% compared to ¥777,326,655.50 in the previous period[35] - The net profit for the current period is CNY 150,305,849.53, an increase of 11.4% compared to CNY 134,528,372.96 in the previous period[36] - The total profit for the current period is CNY 185,481,143.05, up from CNY 176,258,957.74, reflecting a growth of 7.0%[36] - Basic earnings per share increased to CNY 0.3402 from CNY 0.2806, representing a rise of 21.3%[37] - The total comprehensive income attributable to the parent company is CNY 169,936,444.05, compared to CNY 138,781,914.63, an increase of 22.5%[37] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,351,316,871.83, reflecting a 9.60% increase from the end of the previous year[5] - The company's total assets reached ¥4,351,316,871.83, compared to ¥3,970,281,336.21 at the beginning of the period, marking an increase of 9.57%[32] - Non-current assets totaled ¥3,006,850,749.00, an increase from ¥2,737,358,338.02, reflecting a growth of 9.83%[32] - Cash and cash equivalents decreased to ¥239,571,890.16 from ¥380,848,368.48, reflecting a decline of 37.06%[31] - The company's retained earnings rose to ¥1,083,003,204.78, up from ¥937,198,743.68, indicating a growth of 15.57%[33] - Accounts receivable increased to ¥522,881,051.42, up 41.16% from ¥370,485,127.99 at the beginning of the period[31] - Inventory rose to ¥441,543,398.90, representing a 28.48% increase from ¥343,884,908.07[31] - Short-term borrowings increased significantly to ¥581,812,936.82, up 56.23% from ¥372,157,363.65[32] - Short-term borrowings increased by 56.34% compared to the beginning of the year, primarily due to increased working capital needs from higher orders[12] - Contract liabilities surged by 625.89% compared to the beginning of the year, mainly due to increased advance payments received from customers[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,898, with the largest shareholder holding 19.59% of the shares[23] - The company has a total of 99,859,659 shares held by Wanze Group Limited, representing a significant portion of the total share capital[24] - The top 10 unrestricted shareholders include National Social Security Fund with 20,003,156 shares and Wanze Group - Hongta Securities with 17,920,000 shares[24] - The company repurchased 27,196,157 shares, accounting for 5.33% of the total share capital[24] - A total of 168 incentive objects had their 1,665,000 shares of restricted stock released from restrictions on September 5, 2025[27] - The company has not identified any related party relationships among the top shareholders[24] Equity Incentive Plan - The 2025 equity incentive plan includes the grant of 6,000,000 shares of restricted stock at a price of 7.35 RMB per share[28] - The first grant of the 2025 equity incentive plan involves 572,250 shares, with 217 individuals as incentive objects[28] - The company plans to repurchase and cancel 564,800 shares of restricted stock from 47 former employees who did not meet the release conditions[26] - The company’s stock incentive plan was approved in the 2025 third extraordinary general meeting[27] - The company disclosed the audit opinions and public notice regarding the 2025 equity incentive plan on July 8, 2025[28] - The company granted 571,350 restricted shares to 208 incentive recipients at a price of ¥7.35 per share as part of its 2025 equity incentive plan[29] Cash Flow - Cash flow from operating activities generated a net amount of CNY 16,637,887.10, down from CNY 51,107,891.87, indicating a decrease of 67.5%[37] - Cash flow from investing activities resulted in a net outflow of CNY 387,069,998.38, slightly improved from a net outflow of CNY 408,664,417.55 in the previous period[38] - Cash flow from financing activities generated a net inflow of CNY 202,274,702.50, down from CNY 289,621,583.34, a decrease of 30.1%[38] - The company’s cash and cash equivalents at the end of the period amounted to CNY 212,779,656.08, compared to CNY 190,258,871.05 at the end of the previous period, an increase of 11.8%[38] Operating Costs - The company's operating costs increased by 38.09% year-over-year, driven by significant revenue growth in the high-temperature alloy business[17] - Total operating costs amounted to ¥756,387,110.22, up 20.11% from ¥629,548,216.13 in the prior period[35] - The company reported interest expenses of CNY 28,069,769.36, up from CNY 26,169,076.43, reflecting an increase of 7.3%[36] - The weighted average return on equity rose to 3.30%, an increase of 0.42 percentage points from the previous year[5]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Points - The company Wanze Industrial Co., Ltd. held its 52nd meeting of the 11th Board of Directors on October 13, 2025, via communication means, with all 6 directors present [1] - Several important resolutions were passed during the meeting, including amendments to the company's articles of association and governance systems, the reappointment of an auditing firm, and the convening of a temporary shareholders' meeting [1] Group 1 - The resolution to amend the company's articles of association and governance systems was unanimously approved with 6 votes in favor, requiring further approval from the shareholders' meeting [1] - The resolution to reappoint Zhengdan Zhiyuan (Shenzhen) Accounting Firm as the auditing institution for the year 2025 was also unanimously approved, pending shareholders' meeting approval [1] - A resolution to convene the fourth temporary shareholders' meeting of 2025 was passed, with details available in the relevant notice [1]